Perjeta (pertuzumab) 420 mg/14 mL

Perjeta 420mg/14mL contains Pertuzumab, a humanized monoclonal antibody that targets the HER2 receptor on cancer cells. It is used as part of combination treatment for certain HER2-positive breast cancers.

Key Information

• Active Ingredient: Pertuzumab
• Strength: 420mg/14mL
• Form: Concentrate for intravenous infusion
• Uses: Used with other cancer treatments for certain cases of HER2-positive metastatic and early breast cancer.
• Administration: Given by intravenous infusion under the supervision of a qualified healthcare professional.
• Common Side Effects: Diarrhea, hair loss, fatigue, nausea, rash and peripheral neuropathy may occur.
• Important: Perjeta may cause serious heart problems and infusion-related reactions. Cardiac function should be monitored as directed by a healthcare professional.

Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Consult a qualified healthcare professional before starting or changing any medication.